Author

K. Broderick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Assay:proteomics· 3 Assay:DNA methylation· 2 Research Focus:host-pathogen & immune response· 2 Organism:non-human primate· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

D. B. Weiner· 3 shared K. Schultheis· 3 shared A. Patel· 2 shared D. W. Kulp· 2 shared L. Humeau· 2 shared M. Purwar· 2 shared N. Chokkalingam· 2 shared S. Ramos· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

D. B. Weiner

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model

S. Jiang, S. Wu, G. Zhao, Y. He, L. Bao, J. Liu, C. Qin, J. Hou, Y. Ding, J. Wu, J. Yan, L. Humeau, A. Patella, D. B. Weiner, K. Broderick, B. Wang

This study compares a wild-type SARS-CoV-2 spike protein DNA vaccine with an optimized sequence in a mouse model, showing enhanced immune responses and protection against viral challenge.

bioRxiv · Aug 13, 2021Immunology

Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection

K. Konrath, K. Liaw, Y. Wu, X. Zhu, S. Walker, Z. Xu, K. Schultheis, N. Chokkalingam, N. J. Tursi, J. Du, M. Sullivan, M. Purwar, A. Moore, V. Machado, I. Maricic, , D. W. Kulp

This study develops glycan-modified SARS-CoV-2 nanoparticle vaccines that induce potent neutralizing antibodies and single-dose protection against SARS-CoV-2 in multiple animal models.

bioRxiv · Apr 28, 2021Immunology

Live virus neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 variants following INO-4800 vaccination of ferrets

S. Riddell, S. Goldie, A. McAuley, M. J. Kuiper, P. A. Durr, K. R. Blasdell, M. Tachedjian, J. D. Druce, T. R. F. Smith, K. Broderick, S. S. Vasan

This study evaluates the neutralization of SARS-CoV-2 variants 501Y.V1 and 501Y.V2 by sera from ferrets vaccinated with INO-4800, finding reduced titres against 501Y.V2 compared to G614.

bioRxiv · Apr 17, 2021Immunology

SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients

D. W. Kulp, S. Walker, N. Chokkalingam, E. L. Reuschel, M. Purwar, Z. Xu, E. Y. Gary, K. Y. Kim, K. Schultheis, J. Walters, S. Ramos, T. R. F. Smith, K. Broderick, P. Tebas, A. Patel, D. B. Weiner

The paper describes a rapid serological assay to detect functional antibodies blocking ACE2 recognition in vaccinated animals and infected patients.

bioRxiv · Jun 17, 2020Immunology

Establishment of a pig influenza challenge model for evaluation of monoclonal antibody delivery platforms

A. McNee, T. Smith, B. Holzer, C. Becky, E. Bessell, G. Guibinga, H. Brown, K. Schultheis, P. Fisher, S. Ramos, A. Nunez, M. Bernard, V. Martini, T. Chrun, Y. Xiao, , E. Tchilian

This study establishes a pig influenza model to evaluate monoclonal antibody efficacy against H1N1, showing dose-dependent reduction in viral load and lung pathology.

bioRxiv · Mar 12, 2020Immunology